Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Dihydropyridine calcium antagonist co-crystal and preparation method and application thereof

A dihydropyridine calcium antagonism and co-crystal technology, applied in the field of crystal form medicines, can solve problems such as unsatisfactory stability, unsatisfactory curative effect of levamlodipine maleate, etc. - X-ray powder diffraction data, the effect of improving solubility and stability

Inactive Publication Date: 2019-10-25
FUDAN UNIV +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although levamlodipine besylate has good curative effect and few side effects, it is deeply trusted by patients, but the eutectic crystal form of levamlodipine besylate, especially the hydrated eutectic crystal form, has unsatisfactory stability
The benzenesulfonic acid was replaced by maleic acid to develop levamlodipine maleate. Although the stability of the eutectic crystal form was slightly improved, studies have shown that the curative effect of levamlodipine maleate is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dihydropyridine calcium antagonist co-crystal and preparation method and application thereof
  • Dihydropyridine calcium antagonist co-crystal and preparation method and application thereof
  • Dihydropyridine calcium antagonist co-crystal and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of Levoamlodipine Benzoate Crystals

[0047] 1) Weigh 2.04 grams of levoamlodipine free base, add it to 4.5 mL of aqueous solution, and stir at room temperature until completely dissolved;

[0048] 2) Prepare an aqueous solution of benzoic acid with a concentration of 1M at room temperature, and add 5 mL of the aqueous solution of benzoic acid to the solution of 1) dropwise within 30 seconds under stirring at room temperature;

[0049] 3) Transfer the above-mentioned salt-forming reaction solution to a reaction kettle, increase the temperature of the reaction solution to 50°C, keep it warm for 5 hours, and then let it stand and cool to 5°C to obtain a large number of needle-shaped or rod-shaped colorless, transparent, and uniform crystal product;

[0050] 4) Filter the obtained crystalline product under reduced pressure, wash the original crystalline solution, and wash with a water solvent at 5°C to obtain, figure 1 is a schematic diagram of the crystal st...

Embodiment 2-8

[0052] The preparation method is the same as in Example 1, and its specific process parameters are shown in Table 1.

[0053] Table 1 embodiment 2-8 process parameter

[0054]

Embodiment 9

[0056] X-ray single crystal diffraction test

[0057] Taking the levamlodipine benzoate eutectic crystal prepared in Example 1 as an example, the crystal quality and size of the selected crystal meet the requirements of the test instrument, and the X-ray single crystal diffractometer of the Apex Duo model of Bruker, Germany is used to test, and the test parameters Follow the strategy established by the instrument. The test temperature is 296K, with Mo-Kα radiation Diffraction data were collected in ω-scan mode and Lp correction was performed. Absorption correction was performed using the SADABS program. The structure is analyzed by the direct method, all non-hydrogen atoms are found by the difference Fourier method, all hydrogen atoms on carbon and nitrogen are obtained by theoretical hydrogenation, and the structure is corrected by the least square method. All parsing processes are completed using the SHELXTL program package.

[0058] In the above measurement, the crysta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a dihydropyridine calcium antagonist co-crystal and a preparation method and application thereof. The molecular formula of the co-crystal is (C20H25ClN2O5).(C6H5COOH).(Y)n, wherein Y is any one of water molecule, ethanol molecule or isopropanol molecule, n is greater than or equal to 0 and less than or equal to 3, the co-crystal is crystallized in a triclinic crystal system and a P1 chiral space group, the unit cell dimensions are that alpha=97.1-97.5 degrees, beta=92.2-92.6 degrees, and gamma=111.5-112.1 degrees. According to the dihydropyridine calcium antagonist co-crystal and the preparation method and application thereof, the solubility and stability of an existing levamlodipine co-crystal crystal form are improved, and potentially, improvement of tablet stability of antihypertensive drugs and improvement of bioavailability in large-scale tablet production are facilitated.

Description

technical field [0001] The invention relates to the technical field of crystalline drugs, in particular to a dihydropyridine calcium antagonist co-crystal and a preparation method and application thereof. Background technique [0002] Due to the advantages of stability, reproducibility, bioavailability and operability, crystalline drugs are preferred in pharmaceutical preparations. Crystalline drugs include polymorphic forms, hydrates, solvates, and salts of drug molecules. Different crystal forms of drugs have significant differences in their physical and chemical properties, which will directly affect their dissolution and absorption efficiency under physiological conditions, and further affect the bioavailability and clinical efficacy of drugs. [0003] As a fourth-generation dihydropyridine calcium ion antagonist antihypertensive drug for the treatment of hypertension, levamlodipine is deeply trusted by doctors and patients due to its high efficacy and small side effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D211/90C07C51/43C07C63/06C07C29/78C07C31/08C07C31/10A61P9/12
CPCC07D211/90A61P9/12C07B2200/13
Inventor 凌云周亚明邓名莉杨永泰刘小锋贾瑜朱嘉星
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com